Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review found that low-level laser therapy appears promising in improving hair regrowth and patient satisfaction in androgenetic alopecia, though results should be interpreted cautiously.

This study found that DEFB1 polymorphisms, specifically the rs1800972 CG and GG genotypes, may predict susceptibility to and severity of alopecia areata.

Hair loss in androgenetic alopecia is caused by genetic factors and androgen excess, and can be treated with combined therapies.

In mouse models of alopecia areata, this study found increased dilation of lymphatic vessels in affected mice, with associated changes in gene expression related to vascular growth and immune cell movement.

Prostaglandin D2, found in higher levels in bald scalps, stops hair growth, suggesting that blocking its receptor could potentially treat hair loss.

In this study, Gsdma1/2/3 knockout mice showed reduced epidermal hyperplasia and inflammation when induced by PMA, which was attributed to decreased EGFR-Stat3/Akt signaling due to a decrease in related ligands.

This research found that Dlx3 plays a central role in hair formation and regeneration, with its absence leading to alopecia through disrupted differentiation and signaling pathways.

This article reports a case of linear lichen planus developing along the lines of Blaschko during intramuscular triamcinolone acetonide therapy for alopecia areata multiplex.

This study found that multidisciplinary group medical visits for patients with alopecia areata improved patient satisfaction, knowledge, and access to care at Lahey Hospital and Medical Center.

This study reports that topical fish oil treatment in GsdmA3 Dfl/+ mice increased cellular proliferation and macrophages but did not affect COX-2 expression related to psoriasis-like skin changes.

This article reviews androgenetic alopecia, detailing its genetic and hormonal causes, clinical presentations, diagnosis, and treatment options, but it reports no new clinical findings.

In a study using mouse models, researchers developed a gelatin methacryloyl scaffold with calcium-doped silica nanoparticles loaded with deferoxamine, which significantly improved skin flap survival and hair follicle growth, suggesting potential clinical applications in tissue regeneration.

This case study presents what is reportedly the first association of Graham Little-Lassueur Syndrome with chronic hepatitis C, observed in a 47-year-old female patient.

This case report identifies an adolescent with symptoms indicative of Dunnigan-type partial lipodystrophy, emphasizing the need for early diagnosis to manage associated metabolic complications and improve self-esteem.

This study introduced the Lichen Planus Activity and Damage Index (LiPADI), which effectively assesses the severity and progression of lichen planus, aligning well with other clinical indicators.

The authors concluded that their new grading system can effectively classify early female pattern hair loss and evaluate treatment progress.

This study found that FDA-approved low-level light/laser therapy devices significantly increased hair density in individuals with pattern hair loss compared to sham devices.

In this randomized controlled trial, the topical application of a PGA solution significantly increased hair density in patients with androgenetic alopecia compared to placebo, with no adverse reactions reported over 24 weeks, suggesting its potential as a safe and effective treatment option.

In this retrospective review, increased frequencies of certain HLA-DRB1 alleles and low vitamin D3 levels were observed in men with androgenetic alopecia, suggesting an association with immunogenetic factors and potential relevance for screening and treatment decisions.

This review discusses low level laser therapy for hair loss but reports no new research findings; it serves as an introduction to understanding existing knowledge before upcoming evaluations of recent studies.

This study found that Gp₄G increased hair length, papilla cell numbers, and versican deposition in treated animals, potentially through alterations in hair follicle phases and nucleotide concentrations.

The study by Godfrey et al. highlights a potential link between GLP-1 receptor agonists, specifically semaglutide and tirzepatide, and the risk of alopecia, emphasizing the need for further investigation and patient awareness.

This study observed that a combination of sinapic acid and glabridin from Zhimo herbal extract improved hair growth and reduced oxidative stress in a DHT-induced model of androgenetic alopecia in mice by preventing ferroptosis and stabilizing β-Catenin, offering potential application for AGA treatment.

This article presents a case study of a 16-year-old male with GAPO syndrome, characterized by growth retardation, alopecia, pseudoanodontia, and optic atrophy, who sought dental treatment for missing teeth.

This study found that GLP-1 receptor agonists are linked to a 40% increased risk of non-scarring alopecia in adults, mainly due to weight loss-induced micronutrient deficiencies, with semaglutide and tirzepatide showing the highest hair loss signals.

In this study, a novel CT@GA-gel hybrid hydrogel was developed for diabetic wound treatment, demonstrating improved mechanical properties, tissue adhesion, and chronic wound healing benefits, including immune regulation and re-epithelialization, due to enhanced crosslinking and ROS scavenging by incorporated carbon dots.